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Peroxisome proliferator-activated receptors (PPARs) regulate lipid and glucose homeostasis, are targets of pharmaceuticals, and
are also activated by environmental contaminants. Almost nothing is known about expression of PPARs during human fetal
development. This study examines expression of PPARα, β,a n dγ mRNA and protein in human fetal tissues. With increasing
fetal age, mRNA expression of PPARα and β increased in liver, but PPARβ decreased in heart and intestine, and PPARγ decreased
in adrenal. Adult and fetal mean expression of PPARα, β,a n dγ mRNA did not diﬀer in intestine, but expression was lower in fetal
stomach and heart. PPARα and β mRNA in kidney and spleen, and PPARγ mRNA in lung and adrenal were lower in fetal versus
adult. PPARγ in liver and PPARβ mRNA in thymus were higher in fetal versus adult. PPARα protein increased with fetal age in
intestine and decreased in lung, kidney, and adrenal. PPARβ p r o t e i ni na d r e n a la n dP P A R γ in kidney decreased with fetal age. This
study provides new information on expression of PPAR subtypes during human development and will be important in evaluating
the potential for the developing human to respond to PPAR environmental or pharmaceutical agonists.
1.Introduction
Peroxisome proliferator-activated receptors (PPARs) belong
to the nuclear hormone receptor superfamily and there are
three primary subtypes (α, β/δ,a n dγ)[ 1]. These receptors
play important roles in embryonic and fetal development as
wellasplacentalfunction [2, 3],regulating manycellularand
metabolic processes [4]. PPARs control energy homeostasis,
are important regulators of adipogenesis, lipid metabolism,
inﬂammatory responses, and hematopoiesis, and are impli-
cated in chronic diseases such as diabetes, obesity and
atherosclerosis [5–8]. PPARβ and γ have roles in early
embryonicsurvivalandimplantation [9,10].PPARsregulate
gene expression by binding to speciﬁc DNA sequences,
peroxisome proliferator response elements (PPREs), in the
promoter regions of target genes. Prior to DNA binding
PPAR forms a heterodimer with the retinoid X receptor
(RXR) [11, 12]. A number of endogenous ligands have
been identiﬁed for each PPAR subtype, including long-chain
fatty acids, polyunsaturated fatty acids such as linoleic and
arachidonic acids, saturated fatty acids, and eicosanoids [1].
A variety of synthetic ligands have been developed for phar-
maceutical purposes to treat chronic diseases such as hyper-
lipidemia, diabetes, and metabolic syndrome. In addition,
some chemicals and environmental contaminants activate
PPARs,forexample, phthalates,tri- and dichloroacetic acids,
trichloroethylene, and the perﬂuorinated alkyl and sulfonyl
acid compounds (PFAAs) [11–14].
PFAAs, including perﬂuorooctanoic acid (PFOA), per-
ﬂuorononanoic acid (PFNA), and perﬂuorooctane sulfonate
(PFOS), are highly stable molecules with chemical properties
that make them excellent surfactants [15]. For many years
these chemicals were widely used in industrial applications
and are now found as persistent environmental contam-
inants that are also present in the tissues and serum of
wildlife and humans [15–17]. In laboratory studies, prenatal2 PPAR Research
exposure of rodents to these compounds produces dose-
related eﬀects on pre- and postnatal survival, developmental
delay, and deﬁcits in postnatal growth [18–23]. PFAAs
activate PPARα, and the developmental toxicity of PFOA
and PFNA in the mouse was shown to be dependent on
expressionofPPARαinthefetus(eﬀectsofprenatalexposure
to PFOA or PFNA that occur in wild-type mice were not
observed in PPARα knockout oﬀspring) [24, 25]. PPARs
are expressed in the mouse embryo and fetus (reviewed in
[26]), and prenatal exposure to PFAAs was shown to change
gene expression in the pre- and postnatal livers in a pattern
indicative of activation of PPAR as well as the CAR nuclear
receptor [27–29].
Almost nothing is known about expression of PPAR
during human development. At the present time, a search
of the literature revealed only one paper that described the
expression of PPARs in the human fetus, and that paper
described expression in the gastrointestinal (GI) tract [30].
This gap in scientiﬁc knowledge of PPAR expression during
human development requires attention as PFAAs, which
activatePPAR,altergeneexpression,andhavedevelopmental
toxicity in the rodent, are pervasive in the environment and
have been found in serum and blood samples of populations
around the world, including samples from infants, children,
and in umbilical cord blood and milk (indicating prenatal
and postnatal exposure of infants) [17, 31–36]. Thus, in
order to evaluate the potential for these environmental
compounds, and others, to aﬀect human fetal development,
it is important to have information regarding the expression
of PPARs in the developing human fetus. The present study
reports mRNA and protein expression for PPARα,β,andγ in
embryonic day (ED) 54 to 125 human fetal liver, heart, lung,
kidney, stomach, intestine, adrenal, spleen, and thymus.
2.Methods and Materials
2.1. Human Fetal and Adult Samples. Human fetal tissues
ranging in age from embryonic day (ED) 54 to 125 were
obtained from the Birth Defects Research Laboratory at
the University of Washington, Seattle. The collection of
tissue specimens from clinically aborted fetuses by the Birth
Defects Research Laboratory (including informed consent
for the donation and all procedures) was conducted with
Human Subjects Institutional Review Board (IRB) approval.
At the EPA, the study was reviewed by the Oﬃce of Human
Research Ethics, UNC Biomedical IRB, and approved by
the National Health Eﬀects and Environmental Research
Laboratory (NHEERL) Human Research Protocol Oﬃce
(HRPO).
Tissues were snap frozen as soon as possible after
collection and stored at −80
◦C until shipped on dry ice.
On arrival at EPA, samples were stored at −80
◦C until
processed for total RNA and protein. The nine tissues ana-
lyzed included liver, heart, lung, kidney, stomach, intestine,
adrenal, spleen, and thymus. Prior to processing the fetal
t i s s u e st op r e p a r eR N Aa n dp r o t e i n ,s a m p l e sw e r ew e i g h e d
and smaller samples were designated for RNA preparation
only, while larger samples were divided for both RNA and
protein preparation, and any excess sample was returned
(still frozen) for storage at −80
◦C. Handling during the
weighing and division of samples was done over dry ice to
the extent possible to minimize thawing. Adult total RNA
for the 9 tissues examined in the study was obtained from
FirstChoice Human Total RNA Survey Panel, Ambion, Inc,
(each adult sample consisted of pooled total RNA from
3 individuals). In addition, tissue samples from 23 adult
human livers were available for comparison of PPAR mRNA
expression in adult and fetal liver. These samples were
obtained from CellzDirect, Inc. (Durham, NC). Total RNA
was prepared from the frozen adult liver tissue samples and
qPCR performed, as described for the fetal samples.
2.2. qPCR Experimental Design and Procedures. Each tissue
was run in separate qPCR experiments (e.g., liver samples
were not run with those of any other tissue). In the qPCR
experiments, expression of PPARα, β, γ and an internal
c o n t r o lg e n ew e r ee x a m i n e do ne a c hp l a t e ,a n ds a m p l e so n
the plate included 2 replicates of each fetal sample and of the
appropriate pooled adult tissue (FirstChoice Human Total
RNA). In cases where there were too many samples of a
tissue to run all of the reactions on one plate, the samples
w e r er u na c r o s s2p l a t e ss u c ht h a te a c ha g ew a sr e p r e s e n t e d
as equally as possible on each plate. The actual number of
samples examined for each tissue is stated in the results
section, but the number available ranged from 23 to 46
specimens,exceptforthymuswhichhad11specimens.PPAR
gene expression was expressed relative to an internal control
gene. The fetal samples of each tissue were examined for
expressionofβ-actin,β2-microglobulin,andglyceraldehyde-
3-phosphate dehydrogenase (GAPDH), as potential internal
control genes. Regression analysis of cycle threshold (Ct)
was performed for each potential control gene to detect any
changesinexpressionwithage.Basedonfavorableregression
outcomes in all of the tissues (no signiﬁcant change with
age), β2-microglobulin (B2M) was selected as the internal
control gene (data not shown).
Tissue was homogenized and extracted in TRI Reagent
(Sigma Chemical, St. Louis, MO) according to the manu-
f a c t u r e r ’ sd i r e c t i o n s ,a n dR N Ap e l l e t sw e r es t o r e di n7 0 %
ethanol at −80
◦C until further use. Following resuspension
in nuclease-free water (Promega Corporation, Madison,
WI), the RNA was quantiﬁed and evaluated for purity
(260nm/280nm and 260nm/230nm ratio) using a Nan-
oDrop ND-1000 spectrophotometer (NanoDrop Technolo-
gies,Wilmington, DE). Prior to qPCR, 2μg total RNA was
digested using 2 units of DNaseI (Promega Corporation,
Madison, WI) for 30min at 37
◦Cf o l l o w e db y1 0 m i na t
65
◦Ci nab u ﬀer containing 40mM Tris (pH 8.0), 10mM
MgSO4,a n d1 m MC a C l 2. The DNase-treated RNA was
then quantiﬁed using a Quant-iT RiboGreen RNA assay
kit according to the manufacturer’s protocol (Invitrogen
Corporation, Carlsbad, CA). Approximately 1μg of the
DNase-treated RNA was reverse transcribed using a High-
Capacity cDNA Archive Kit according to the provided pro-
tocol (Applied Biosystems). Ampliﬁcation was performed on
an Applied Biosystems model 7900HT Fast Real-Time PCR
Systeminduplicateusing25ngcDNAandTaqManUniversalPPAR Research 3
PCR Master Mix (Applied Biosystems) in a total volume of
12μl. The following TaqMan assays (Applied Biosystems)
were included in the study: PPARα (Hs00947539 m1),
PPARβ (Hs00602622 m1), PPARγ (Hs00234592 m1), β-
actin (Hs99999903 m1), GAPDH (Hs99999905 m1), β-2
microglobulin (Hs99999907 m1).
PPARmRNACtvalues,calculatedbyAppliedBiosystems
SDS2.2.2 software, were normalized by subtraction of the
Ct for the internal control, B2M, generating δCt values.
The mean δCt for each sample was calculated from the
2 replicates and then analyzed to evaluate changes in
expression with fetal age (regression analysis). Diﬀerences in
expressionbetweensubtypesweredeterminedusingANOVA
of all mean δCt values (without regard to age), with Bonfer-
roni’s post-test applied for pairwise comparisons (Prism 4.0,
GraphPad Software, San Diego, CA). Data are graphed as a
log plot of 2−δCt. For all tissues except liver, a comparison of
thefetalsampleswiththesingleadultpooledsamplewasper-
formed using Ct values and a t-distribution test (sample size
less than 30) or the Z-distribution test (sample size equal to
or greater than 30) to determine the probability that an adult
value of this extreme or more extreme would be found in
the distribution of fetal values (using probability calculators
available on-line at http://faculty.vassar.edu/lowry/tabs.html
or http://davidmlane.com/hyperstat/z table.html). As the
internal control gene expression was not the same in adult
and fetal tissues, Ct values, and not δCt values, were used
for this comparison. Data comparing fetal (mean Ct of 2
replicates) and adult Ct (each replicate shown in the plot)
are graphed as a vertical scatter plot of Ct. For the liver,
there were 23 adult liver specimens available for comparison
with the fetal liver samples. The adult samples were from
both males and females and ranged in age from 21 to 86
years, but analysis of either Ct or dCt showed no eﬀect of
either sex or age on the expression of PPARα, β,o rγ or
B2M (data not shown). The adult and fetal liver samples
had comparable levels of the internal control gene, B2M, and
thus it was possible to compare the normalized Ct values
(dCt) using ANOVA with Bonferroni’s post-test applied for
pairwise comparisons (Prism 4.0, GraphPad Software, San
Diego, CA).
2.3. Western Blot Experimental Design and Procedures. Sam-
ples of each tissue were run in separate Western blot
experiments (e.g., liver samples were not run with those of
any other tissue). In general, most of the tissues required
2-3 Western blots to accommodate all of the samples (only
12 sample lanes were available per gel), and the samples
were blocked across blots such that the age range was
represented as uniformly as possible on each blot. The actual
number of samples examined for each tissue is stated in
the results section, but the number available ranged from
5 to 36 specimens, and only thymus and spleen had fewer
than 22 specimens. Each blot was examined for expression
of one of the PPAR subtypes and for the internal control
protein. GAPDH was selected as the internal control protein
as expression did not change with age (based on regression
analyses of GAPDH protein expression across age in each
of the 9 tissues, data not shown). A positive control for
antibody detection of PPARα, β,o rγ was also run on each
blot. Positive controls were Hep G2 whole cell extract (Santa
Cruz, SC-2227), Jurkat cell nuclear extract (Santa Cruz, SC-
2132), and U937 whole cell extract (Santa Cruz, SC-2239),
for expression of PPARα, β,o rγ, respectively. After all tissues
wereexamined inthis manner, additional Westernblots were
run in which all 9 tissues were represented on the blot, with
most of the tissues from the same 91-day-old fetus (to the
extent possible, as not all tissues were available from any
single fetus, and thymus was not available from a 91-day
fetus). Three “across-tissue” blots were run for each PPAR
subtype (i.e., n = 3 fetuses per tissue examined in the
“across-tissue” survey).
Western blots were run with 25μgo ft o t a lc e l ll y s a t e
or positive control per lane. All gels were 7.5% acrylamide
precast gels (Biorad, Hercules, CA) and were run for
90min at 125V. Protein transfer to nitrocellulose membrane
(Biorad) was done for 40min using the Biorad semidry
transfer system. Membranes were blocked for 1hr in 5%
milk and incubated overnight in primary antibody in 5%
milk. Primary antibodies for PPARα (SC-9000) and PPARγ
(SC-7196) were obtained from Santa Cruz Biotechnologies
(Santa Cruz, CA) and used at a dilution of 1:200. PPARβ
(Abcam 21209) antibody was obtained from Abcam, Inc,
(Cambridge, MA) and used at 1:750 dilution. Antibody for
GAPDH (SC-25778) was from Santa Cruz Biotechnologies
andwasdilutedat1:10,000. Afterovernightincubationwith
primary antibody, blots were probed 1hr with a horseradish
peroxidase-conjugated secondary antibody in 5% milk.
Secondaryantibodies werediluted 1:5000 andincluded goat
anti-rabbit Jax 111-035-144 (West Grove, PA), goat anti-
rabbit KPL 074-1506 and rabbit anti-goat KPL 14-13-06
(KPL, Gaithersburg, MD). Chemiluminescence was imaged
using a Biorad Fluor-S machine with 2 or 5min exposures.
Biorad Quantity One software was used to perform volume
rectiﬁcation densitometry with background subtraction on
the chemiluminescence images, generating data for both the
PPAR and GAPDH bands. PPAR protein expression was
expressed relative to the internal control gene, GAPDH, and
regression analysis of the relative values was performed to
detect any signiﬁcant change in slope with age (Prism 4.0,
GraphPad Software, San Diego, CA).
3. Results
The expression of PPARs is presented for each tissue,
reporting any change in expression of protein or mRNA
with gestational age, comparing the relative level of mRNA
expression of the isotypes, and comparing mRNA expression
inthefetalorgantothatobserved inthehumanadultsample
of that tissue. Protein and mRNA for all PPAR isotypes were
detected in all of the 9 tissues and the results are summarized
in Table 1, which also lists the tissues from highest to lowest
expression of mRNA for each PPAR. Table 2 summarizes the
relative expression of the isotypes within each tissue. The
data is shown using the same presentation format for each
tissue. A full narrative presentation is given for the ﬁrst tissue
presented (liver) and, for the sake of brevity, the results for4 PPAR Research
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Figure 1: Liver. (a) The expression of PPARα, β,a n dγ mRNA is shown across the fetal age range. Log plot of mean ± S E MC ti sn o r m a l i z e d
toβ-2-microglobulin(B2M).(b)ThefetalexpressionofPPARα,β,andγ isshownrelativetoexpressioninadultliver.Eachsymbolrepresents
the mean Ct value of 2 replicates for each fetal (open circles) and adult (ﬁlled circles) sample (overall mean for each group is shown
as a horizontal line). (c) PPARα, β,a n dγ protein expression is shown across the fetal age range. Western blot density is normalized to
glyceraldehyde-3-phophate dehydrogenase (GAPDH). Up arrowhead indicates PPARα, down arrowhead PPARβ, and diamond PPARγ.I f
only one sample was available for a particular age, then an error term could not be calculated and no SEM bar is shown. Regression analysis
evaluated change with age. Dashed lines in graphs of C are the 95% conﬁdence interval.PPAR Research 5
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Figure 2: Heart. (a) The expression of PPARα, β,a n dγ mRNA is shown across the fetal age range. Log plot of mean ± S E MC ti sn o rm a l i z e d
to β-2-microglobulin (B2M). (b) The fetal expression of PPARα, β,a n dγ is shown relative to expression in adult heart. Each symbol
represents the mean Ct value of 2 replicates for each fetal (open circles) sample and adult (ﬁlled circles) individual replicates are shown
(overall mean for each group is shown as a horizontal line). (c) PPARα, β,a n dγ protein expression is shown across the fetal age range.
Western blot density normalized to glyceraldehyde-3-phophate dehydrogenase (GAPDH). Up arrowhead indicates PPARα, down arrowhead
PPARβ, and diamond PPARγ. If only one sample was available for a particular age, then an error term could not be calculated and no SEM
bar is shown. Regression analysis evaluated change with age. Dashed lines in graphs of C are the 95% conﬁdence interval.6 PPAR Research
other tissues omit repetitive explanations which apply to all
the data sets.
3.1. Liver. Human fetal liver expressed PPARα, β,a n dγ
mRNA from ED54–125 (data acquired from 39 fetuses).
Expression of PPARα and PPARβ increased signiﬁcantly
while PPARγ remained unchanged across the age range
(Figure 1(a), P<. 01 and .05, resp.). Expression levels of
PPARα and γ across all ages were not signiﬁcantly diﬀerent
andbothweremorehighlyexpressedthanPPARβ(P<. 001).
β2M mRNA expression was considerably higher than any of
thePPARsubtypes(mean ±SEMCtacrossallages,notethat
a lower Ct signiﬁes more abundant mRNA than a high Ct:
β2M = 22.4±0.3, PPARα = 28.2±0.3, PPARβ = 30.1±0.3,
PPARγ = 28.6 ± 0.3). The expression of PPAR mRNA in
the fetal liver was compared to that in 23 adult human
liver samples. The adult samples were from both males and
females and ranged in age from 21 to 86 years, but analysis
showed no eﬀect of either sex or age on the expression of
PPARα, β, γ, or B2M (data not shown). The expression
of B2M, the internal control gene, in adult and fetal liver
samples was not signiﬁcantly diﬀerent (21.9±0.2, 22.4±0.3,
mean±SEM,resp.),andthusitwaspossibletoanalyzePPAR
values normalized to B2M (dCt). Analysis of unadjusted Ct
or dCt gave the same outcomes, and Figure 1(b) shows plots
of the Ct values for adult and fetal livers. The human fetal
and adult livers expressed PPARα and β mRNA at levels
that were not signiﬁcantly diﬀerent (Figure 1(b)),but PPARγ
was signiﬁcantly higher in the fetal liver (P<. 001, lower
mean Ct indicates higher mRNA present in a sample). The
overall outcome for PPARα and β was the same from the
pooled total RNA from 3 donors (Ambion FirstChoice liver
sample, data not shown) as that from the 23 individuals;
adult and fetal liver expression did not signiﬁcantly diﬀer.
The Ambion FirstChoice pooled adult liver RNA indicated
that PPARγ did not diﬀer between adult and fetal livers,
but the data from the 23 individuals showed a signiﬁcantly
higher expression in the fetus, and the larger “n” of that
assay would lend support to the validity of that outcome.
In the fetal liver, PPARα, β,a n dγ protein expression did
not change with fetal age (Figure 1(c); data from 22 fetuses,
ED54–120).
3.2. Heart. PPARα and γ expression did not change, but
PPARβ expression decreased (P<. 0001) with fetal age
(Figure 2(a), ED54–125, n = 46 fetuses). PPARα,P P A R β,
and PPARγ relative expressions are shown in Table 2 and
diﬀerences between isotypes were signiﬁcant at P<. 001.
β2M mRNA expression was higher than PPAR (mean Ct ±
SEM: β2M = 24.2 ± 0.8, PPARα = 28.7 ± 0.1, PPARβ =
30.8 ± 0.1, and PPARγ = 31.9 ± 0.1). Fetal PPARα, β,
and γ mRNA expression was lower than that of the adult
sample (Figure 2(b); P<. 05,.001,.001, resp.). PPAR protein
expression did not change with fetal age (Figure 2(c); 36
fetuses, ED54–125).
3.3. Lung. PPAR mRNA expression in fetal lung did not
change with age (Figure 3(a), ED54–120, n = 27 fetuses).
PPARα was the most highly expressed isotype (P<. 001,
Table 2). β2M mRNA expression was higher than PPAR,
(mean Ct ± SEM: β2M = 24.0 ± 0.2, PPARα = 28.4 ± 0.1,
PPARβ = 29.4 ± 0.1, and PPARγ = 29.5 ± 0.2). Fetal and
adult PPARα and β mRNA expressions were not diﬀerent,
but fetal PPARγ was lower (Figure 3(b); P<. 05). PPARα
protein levels decreased (P<. 05), but PPARβ and γ did
not change with fetal age (Figure 3(c), ED57 to 120, n = 27
fetuses).
3.4. Kidney. PPAR mRNA expression did not change with
age (Figure 4(a), 46 fetuses, ED54–125). PPARγ expression
was higher than PPARα and PPARβ (P<. 05, P<. 001,
resp.), and PPARα was higher than PPARβ (P<. 001). β2M
mRNA expression was higher than PPAR (mean Ct ± SEM:
β2M = 24.5±0.1, PPARα = 29.3±0.1, PPARβ = 30.0±0.1,
PPARγ = 28.9 ± 0.1). PPARα and β fetal mRNAs were lower
than in the adult (Figure 4(b); P<. 01, <.0001, respectively),
but PPARγ was similar (P = .07). PPARβ protein expression
did not change with fetal age (P = .09), but PPARα and γ
decreased (P<. 05, Figure 4(c); 36 fetuses, ED57–125).
3.5. Stomach. PPAR mRNA expression did not change with
age(Figure5(a),35fetuses,ED54–120).PPARγ wasthemost
highly expressed isotype (P<. 001, Table 2). β2M mRNA
expression was higher than PPAR (mean Ct ± SEM: β2M =
28.0 ± 0.3, PPARα = 32.4 ± 0.3, PPARβ = 33.3 ± 0.3, and
PPARγ = 29.8 ± 0.4). PPARα, β,a n dγ mRNA expression
waslowerinfetalthaninadultstomach(Figure5(b);P<. 01,
<.0001, <.05, resp.). PPAR protein expression did not change
with fetal age (Figure 5(c); 26 fetuses, ED59–120).
3.6. Intestine. PPARα and γ mRNA expression did not
changewithage,butPPARβdecreased(P<. 001,Figure6(a),
32 fetuses, ED54–120). PPARα, β,a n dγ were expressed at
similar levels (Table 2). β2M mRNA expression was higher
than PPAR (mean Ct ± SEM: β2M = 21.4 ± 0.2, PPARα =
27.5 ± 0.2, PPARβ = 27.4 ± 0.1, and PPARγ = 27.6 ± 0.3).
Fetal intestinal PPAR mRNA was not signiﬁcantly diﬀerent
from either the adult small intestine or the adult colon
(Figure 6(b)). PPARα protein expression increased (P<
.001), while PPARβ and γ proteins did not change with fetal
age (Figure 6(c); 29 fetuses, ED57–120).
3.7. Adrenal. PPARγ mRNA decreased with age (P<. 05),
while PPARα and β remained unchanged (although P =
.0503 for PPARβ; Figure 7(a), 46 fetuses, ED54–120). PPARα
and β mRNAs were more highly expressed than PPARγ (P<
.001,Table2).β2MmRNAexpressionwashigherthanPPAR,
(mean Ct ± SEM: β2M = 24.2 ± 0.3, PPARα = 29.5 ± 0.3,
PPARβ = 29.2 ± 0.2, and PPARγ = 32.1 ± 0.3). Fetal and
adult PPARα and β m R N A sw e r en o td i ﬀerent, but PPARγ
was lower in fetal adrenal (P<. 05; Figure 7(b)). PPARα
and β protein expression decreased with fetal age (P<. 05,
P<. 001, resp.; Figure 7(c); 36 fetuses, ED67–120).
3.8.Spleen. PPARmRNAexpressiondidnotchangewithage
(Figure 8(a), 23 fetuses, ED67–125). PPARγ was the mostPPAR Research 7
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Figure3:Lung.(a)TheexpressionofPPARα,β,andγ mRNAisshownacrossthefetalagerange.Logplotofmean ±SEMCtisnormalizedto
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the mean Ct value of 2 replicates for each fetal (open circles) sample and adult (ﬁlled circles) individual replicates are shown (overall mean
for each group is shown as a horizontal line). (c) PPARα, β,a n dγ protein expression is shown across the fetal age range. Western blot
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diamond PPARγ. If only one sample was available for a particular age, then an error term could not be calculated and no SEM bar is shown.
Regression analysis evaluated change with age. Dashed lines in graphs of C are the 95% conﬁdence interval.8 PPAR Research
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Figure 4:Kidney.(a)TheexpressionofPPARα,β,andγ mRNAisshownacrossthefetalagerange.Logplotofmean ±SEMCtisnormalized
to β-2-microglobulin (B2M). (b) The fetal expression of PPARα, β,a n dγ is shown relative to expression in adult kidney. Each symbol
represents the mean Ct value of 2 replicates for each fetal (open circles) sample and adult (ﬁlled circles) individual replicates are shown
(overall mean for each group is shown as a horizontal line). (c) PPARα, β,a n dγ protein expression is shown across the fetal age range.
Western blot density normalized to glyceraldehyde-3-phophate dehydrogenase (GAPDH). Up arrowhead indicates PPARα, down arrowhead
PPARβ, and diamond PPARγ. If only one sample was available for a particular age, then an error term could not be calculated and no SEM
bar is shown. Regression analysis evaluated change with age. Dashed lines in graphs of C are the 95% conﬁdence interval.PPAR Research 9
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Figure 5: Stomach. (a) The expression of PPARα, β,a n dγ mRNA is shown across the fetal age range. Log plot of mean ± SEM Ct is
normalized to β-2-microglobulin (B2M). (b) The fetal expression of PPARα, β,a n dγ is shown relative to expression in adult stomach.
Each symbol represents the mean Ct value of 2 replicates for each fetal (open circles) sample and adult (ﬁlled circles) individual replicates
are shown (overall mean for each group is shown as a horizontal line). (c) PPARα, β,a n dγ protein expression is shown across the fetal
age range. Western blot density normalized to glyceraldehyde-3-phophate dehydrogenase (GAPDH). Up arrowhead indicates PPARα,d o w n
arrowhead PPARβ, and diamond PPARγ. If only one sample was available for a particular age, then an error term could not be calculated
and no SEM bar is shown. Regression analysis evaluated change with age. Dashed lines in graphs of C are the 95% conﬁdence interval.10 PPAR Research
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Figure 6: Intestine. (a) The expression of PPARα, β,a n dγ mRNA is shown across the fetal age range. Log plot of mean ± SEM Ct is
normalized to β-2-microglobulin (B2M). (b) The fetal expression of PPARα, β,a n dγ is shown relative to expression in adult small intestine
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Figure 7: Adrenal. (a) The expression of PPARα, β,a n dγ mRNA is shown across the fetal age range. Log plot of mean ± SEM Ct is
normalized to β-2-microglobulin (B2M). (b) The fetal expression of PPARα, β,a n dγ is shown relative to expression in adult adrenal. Each
symbol represents the mean Ct value of 2 replicates for each fetal (open circles) sample and adult (ﬁlled circles) individual replicates are
shown (overall mean for each group is shown as a horizontal line). (c) PPARα, β,a n dγ protein expression is shown across the fetal age
range. Western blot density is normalized to glyceraldehyde-3-phophate dehydrogenase (GAPDH). Up arrowhead indicates PPARα,d o w n
arrowhead PPARβ, and diamond PPARγ. If only one sample was available for a particular age, then an error term could not be calculated
and no SEM bar is shown. Regression analysis evaluated change with age. Dashed lines in graphs of C are the 95% conﬁdence interval.12 PPAR Research
Table 1: Relative RNA
1 expression for each subtype (listed from highest to lowest mean expression), characteristics
2 of RNA and protein
expression across age, and fetal mRNA expression relative to adult.
RNA abundance: high to low RNA change with age Fetal versus adult mRNA Protein change with age
PPARα
Intestine NS NS Increase
Liver Increase NS NS
Lung NS NS Decrease
Heart NS Lower NS
Kidney NS Lower Decrease
Adrenal NS NS Decrease
Thymus NS NS NS
Stomach NS Lower NS
Spleen NS Lower NS
PPARβ
Intestine Decrease NS NS
Adrenal NS NS Decrease
Lung NS NS NS
Kidney NS Lower NS
Thymus NS Higher NS
Liver Increase NS NS
Heart Decrease Lower NS
Spleen NS Lower NS
Stomach NS Lower NS
PPARγ
Thymus NS NS NS
Intestine NS NS NS
Spleen NS NS NS
Liver NS Higher NS
Kidney NS NS Decrease
Lung NS Lower NS
Stomach NS Lower NS
Heart NS Lower NS
Adrenal Decrease Lower NS
1Relative RNA expression based on mean Ct for all samples across all ages for each tissue, listed from highest to lowest mean expression for each subtype.
2Change in RNA and protein expression with age shown as increased, decreased, or not signiﬁcant (NS) and fetal mRNA expression compared to adult
expression shown as higher, lower, or not signiﬁcantly (NS) diﬀerent from adult.
highly expressed isotype (P<. 001, Table 2). β2M mRNA
expression was higher than PPAR (mean Ct ± SEM: β2M =
25.6 ± 0.2, and PPARα = 33.5 ± 0.3, PPARβ = 32.9 ± 0.2,
PPARγ = 28.3±0.3). Fetal PPARα and β m R N A sw e r el o w e r
than in the adult (P<. 01, Figure 8(b)). PPARα, β,a n dγ
protein expression did not change with fetal age (Figure 8(c);
11 fetuses, ED85–125).
3.9. Thymus. PPAR mRNA expression did not change with
age (Figure 9(a), 11 fetuses, ED74–120). PPARγ mRNA
expression was higher than PPARα or β (P<. 001), and that
of PPARβ was higher than PPARα (P<. 01). β2M mRNA
expression was higher than PPAR (mean Ct ± SEM Ct:
β2M = 23.1±0.4, PPARα = 31.3±0.3, PPARβ = 30.0±0.1,
and PPARγ = 27.5 ± 0.3). PPARβ fetal mRNA expression
was higher than in the adult (P<. 05, Figure 9(b)). PPAR
protein expression did not change with fetal age (Figure 9(c);
5 fetuses, ED101–120).
3.10.ComparisonofPPARα,β,γ ExpressionLevelsinDiﬀerent
Tissues. Table 1 lists the tissues in an order based on the
level of RNA expression in fetal tissues such that the ﬁrst
tissue listed for each subtype has the highest and the last
in the list has the lowest expression. The ranking for RNA
expression is based on the mean Ct across all ages for each
tissue. Expression of PPARα mRNA is the highest in the
intestine, liver, and lung and is relatively low in stomach and
spleen.PPARβwasthehighestinintestine,adrenal,andlung,
while expression in spleen and stomach was relatively low.
PPARγ was the highest in thymus, intestine, and spleen, butPPAR Research 13
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Figure 8:Spleen.(a)TheexpressionofPPARα,β,andγ mRNAisshownacrossthefetalagerange.Logplotofmean ±SEMCtisnormaliz ed
to β-2-microglobulin (B2M). (b) The fetal expression of PPARα, β,a n dγ is shown relative to expression in adult spleen. Each symbol
represents the mean Ct value of 2 replicates for each fetal (open circles) sample and adult (ﬁlled circles) individual replicates are shown
(overall mean for each group is shown as a horizontal line). (c) PPARα, β,a n dγ protein expression is shown across the fetal age range.
Western blot density is normalized to glyceraldehyde-3-phophate dehydrogenase (GAPDH). Up arrowhead indicates PPARα,a n dd o w n
arrowhead PPARβ, and diamond PPARγ. If only one sample was available for a particular age, then an error term could not be calculated
and no SEM bar is shown. Regression analysis evaluated change with age. Dashed lines in graphs of C are the 95% conﬁdence interval.14 PPAR Research
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Figure 9: Thymus. (a) The expression of PPARα, β,a n dγ mRNA is shown across the fetal age range. Log plot of mean ± SEM Ct is
normalized to β-2-microglobulin (B2M). (b) The fetal expression of PPARα, β,a n dγ is shown relative to expression in adult thymus. Each
symbol represents the mean Ct value of 2 replicates for each fetal (open circles) sample and adult (ﬁlled circles) individual replicates are
shown (overall mean for each group is shown as a horizontal line). (c) PPARα, β,a n dγ protein expression is shown across the fetal age
range. Western blot density is normalized to glyceraldehyde-3-phophate dehydrogenase (GAPDH). Up arrowhead indicates PPARα,a n d
down arrowhead PPARβ, and diamond PPARγ. If only one sample was available for a particular age, then an error term could not be
calculated and no SEM bar is shown. Regression analysis evaluated change with age. Dashed lines in graphs of C are the 95% conﬁdence
interval.PPAR Research 15
Table 2: Relative RNA expression of PPAR isotypes within each
tissue.
Intestine α = β = γ
Liver α = γ>β
Lung α>β= γ
Heart α>β>γ
Adrenal α = β>γ
Thymus γ>β>α
Spleen γ>α= β
Kidney γ>α>β
Stomach γ>α= β
Relative expression based on mean Ct across ages for all samples of each
tissue.
w a sp o o r l ye x p r e s s e di nh e a r ta n da d r e n a l .A m o n ga l lt h e
tissues, intestine was unique in having high expression of all
three subtypes, although lung expressed high levels of both
PPARα and β. Stomach poorly expressed all three subtypes
relative to the other tissues. Spleen showed weak expression
of both PPARα and β, while expression of PPARβ and γ was
weak in the heart.
Comparison of the relative levels of protein expression
for each PPAR subtype is not presented. The expression
of GAPDH did not change with age, making it a suitable
loading control for normalization of the PPAR densitometry
values from the Western blots for each tissue across age (data
not shown); however, GAPDH expression was substantially
diﬀerent between the tissues and that makes it inappropriate
to compare or rank the normalized expression between the
diﬀerent tissues. Even considering that the levels of GAPDH
were not uniformly expressed in the diﬀerent tissues, it is
clear that there were diﬀerent levels of PPARα, β,a n dγ
proteins in the various tissues. This can be seen in Figure 10
which illustrates the expression of PPAR proteins in all 9
tissues on single blots for each subtype. In these assays, all 9
tissues were present on each blot and, to the extent possible,
the tissues on each blot were from the same 91-day old fetus.
Thymus was only available from 101-, 108-, and 110-day old
fetuses. Three of the cross-tissue assays (each using tissues
from diﬀerent fetuses) were run for each PPAR subtype and
examples of the multiple tissue blots are shown in Figure 10.
4. Discussion
This study provides new information regarding the expres-
sion of PPAR subtypes during human fetal development.
PPARα, β and γ are expressed in the human fetus from
embryonic days 54 to 125. Protein and mRNA for all three
PPAR subtypes were detected in the 9 tissues examined in
this study. In some organs, the expression of mRNA or
protein changed during the developmental period examined.
Relative levels of mRNA expression of the PPAR subtypes
variedbytissue.Insomeorgans,thelevelofmRNAexpressed
was comparable to or higher than that of the adult tissue.
Human fetal expression of PPAR subtypes can be con-
sidered similar to the expression patterns reported for the
laboratory rodent, reviewed in [26]. In mouse and rat, PPAR
mRNA and/or protein was detected during prenatal and
postnatal development for liver, kidney, heart, lung, adrenal,
spleen, vertebra, tissues of the central nervous system (CNS),
brain, adipose, fat, muscle, and skin. The patterns of expres-
sion varied by tissue and were dependent on developmental
stage. It is diﬃcult to make speciﬁc comparisons between
developmentalpatternsofPPARexpressioninthelaboratory
animal and the human fetal tissues of this study as com-
parisons between comparable developmental stages become
complicated following the end of organogenesis [26]. In
the present study, the period of human fetal development
ranged from about 8 to 18 weeks, a period following
organogenesis and encompassing the fetal stage of rapid
growth, diﬀerentiation, and functional maturation of the
organ systems. The end of organogenesis and beginning of
thefetalperiodaregenerallyconsideredtooccurattheendof
theeighthweekofgestation[37]andalandmarkoftheentry
to the fetal stage is the fusion of the secondary palate. Palatal
fusion in human fetuses begins around embryonic day 54
and is generally complete in the 56-57-day-old fetus [37, 38].
In the mouse and rat, palatal fusion occurs on ED14-15
and 16-17, respectively, although this can vary by a day or
two depending on the strain. Thus, it may be reasonable
to consider the ED14 mouse, ED16 rat, and the ED54–56
humanfetaltissuestobeatcomparabledevelopmentalstages
for purposes of comparison of PPAR expression. Restricting
the discussion to that speciﬁc developmental period (end of
organogenesis marked by palatal fusion), the comparisons of
human and rodent PPAR expression are somewhat limited.
Overall, as discussed below, there are similarities, and also
some diﬀerences, in the expression of PPAR in rodent and
h u m a nf e t u s e sa tt h ee n do fo r g a n o g e n e s i s .
In the ED15.5 rat liver, moderate levels of mRNA for
PPARα and β were found and PPARβ protein was reported
in ED15 mouse liver and PPARγ2 protein was detected at a
slightly earlier stage (ED13) in mouse liver [39, 40]. In the
present study, PPARα was highly expressed in the human
fetal liver and relatively abundant compared to other tissues
(only intestine was higher). When evaluated across all ages,
PPARα and γ were more abundant than β in liver.
R a th e a r ta n dl u n ge x p r e s s e dP P A R α and β,a n dP P A R β
protein expression is reported for mouse heart and lung
[40, 41]. In the present study, human fetal lung and heart
had high expression of PPARα a n dl u n gs t r o n g l ye x p r e s s e d
PPARα and β relative to the other organs. In human fetal
heart and lung, PPARα was more abundant than β or γ,a n d
in heart γ was the subtype with the least expression.
The ED15.5 rat and 14.5 mouse kidneys expressed
PPARα mRNA. PPARβ mRNA was found in rat and PPARβ
and γ were weakly detected in the mouse kidney [41, 42].
In human fetal kidney, PPARγ was expressed at higher levels
than α or β,a n dβ was the least abundant subtype in kidney.
We are not aware of any published data regarding
expression of PPAR in thymus or spleen of the developing
rodent. In the human fetal spleen, PPARα and β were
expressed at low but equivalent levels and PPARγ was the
most abundant subtype with relatively high expression (only
those of thymus and intestine were higher). In human fetal
thymus, PPARγ mRNA was very abundant (higher than in16 PPAR Research
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Figure 10: Western blots are shown in which all 9 tissues are present on each blot. On the PPARα blot, all tissues shown by dark bars were
from a single 91-day-old fetus, and adrenal and kidney (white bars) were from diﬀerent 91-day-old fetuses, and thymus was from a 101-day-
old fetus. The blots for PPARβ and PPARγ used samples from a 91-day-old fetus (dark bars, the same set of samples for both PPARβ and γ)
with kidney and thymus samples (white bars) from diﬀerent fetuses (91 and 108 days, resp.). Blot images are labeled to show the location of
the PPAR band, the GAPDH band, and lane containing the positive control (Hep G2 whole cell extract, Jurkat cell nuclear extract, and U937
whole cell extract, for expression of PPARα, β,o rγ, resp.). The densitometry data (PPAR expression normalized to GAPDH) for each gel is
shown above the blot image. Lanes 1–9 contain the samples listed on the x- a x i so ft h eb a rg r a p h s .
any other tissue) and PPARβ and α were detected at lower
levels than PPARγ.
In rat GI tract, mRNAs for PPARα and β,b u tn o t
γ (reported as not detected), were expressed, and PPARβ
protein was reported in mouse GI tissue [40, 41]. The
present study found high expression in intestine for all PPAR
subtypes relative to the other organs, and PPARα, β,a n d
γ mRNAs were at equivalent levels. Stomach, which was
examinedseparately,hadlowerexpressionofallsubtypesrel-
ative to intestine, and PPARγ was the most highly expressedPPAR Research 17
s u b t yp ei ns t o m a c h .H u i ne ta l .[ 30] examined PPAR protein
expression in the fetal human digestive tract (aged 7 to
22 weeks) using immunohistochemistry and found spatial
and temporal patterns of expression in esophagus, stomach,
jejunum, ilium, and colon. In the present study, using qPCR
and Western blotting methods, no change with age was
detected in stomach for expression of PPARα, β,o rγ.H u i n ’ s
report found slightly less PPARα at 19 weeks compared to
12 and 15 weeks of age, while PPARβ and γ were slightly
higher at 15 and 16 weeks, respectively, than at 12 or 19
weeksofgestation.The19-weekobservationsofHuin’sstudy
are just outside the age range of the present study, but
the slight changes in protein reported by Huin diﬀer from
our observations of mRNA and protein at the earlier ages.
The intestinal expression of PPAR reported for the various
regions observed in Huin’s study is similar as an overall
pattern to that found in the present study; however, in the
present study it was not possible to separate regions of the
intestinaltract.HuinreportedincreasingPPARαintheileum
from 12 to 22 weeks of age, similar to the increase with age in
PPARα protein observed from 8 to 18 weeks in the present
study. Similarly, Huin reported that PPARβ and γ protein
expression in the jejunum and ilium was similar across time
(7–16 and 12–22 weeks, resp.), and the present study also
found no signiﬁcant change in protein expression of PPARβ
or γ with age.
An important ﬁnding of the present study is that fetal
tissues can express PPAR at levels equivalent to those of
the adult tissues (or higher in the case of PPARγ in liver
and PPARβ in thymus). However, some caution is needed
as the adult data for each tissue (with the exception of
liver) is based on a pooled total RNA sample from 3 donors
and it is not known whether a similar outcome would be
derived from a larger number of adult donors. However,
in the case of liver, the data from 23 individuals supported
the data from the pooled sample, that is, expressions of
PPARα and β were not signiﬁcantly diﬀerent in adult and
fetal livers. However, the pooled sample did not detect the
increased expression of PPARγ in fetal liver relative to the
adult, as observed in the 23 individual liver samples. Thus,
the adult versus fetal comparison provides data that were
previously not available and represent the only information
for this endpoint. However, it is important to recognize that
comparisons of these data with additional analyses from
larger adult tissue sets would be desirable.
In summary, this study is unique in providing substantial
information on the expression of PPARα, β,a n dγ during
human fetal development. Among the strengths of the study
are the acquisition of both protein and mRNA data from the
same samples, the inclusion of multiple tissues from most
fetuses, and the large number of individuals represented in
the sample set. Representation of tissues across a range of
ages supported an evaluation of whether PPAR expression
changed as development progressed. The qPCR approach
supported estimation of the relative expression of subtypes
within a tissue as well as supporting comparisons of
expression of each subtype across the diﬀerent tissues. As
mentioned in the introduction, an important aspect of this
study was to provide information for use in assessing the
potential for the human fetus to respond to PPAR agonists.
Studies in human fetal tissues of responses to PPAR agonists
are generally not feasible; thus, it is important to at least
have information on the developmental expression of PPAR
and how that compares to adult expression. This study
contributes to our knowledge regarding the expression of
PPAR during development and compares fetal and adult
PPAR expression. An important ﬁnding of the study is that
fetal tissues can have expression levels equivalent to those
of the adult tissues (or higher in the case of PPARγ in liver
and PPARβ in thymus). The role of PPAR subtypes in the
developing fetus remains unclear, but it is likely that these
nuclear receptors have roles similar to those described for
adult tissues, including regulation of energy homeostasis as
well as lipid and glucose utilization. During the fetal stages
examined in this study, the organs undergo rapid growth,
diﬀerentiation, and acquisition of functionality. Exogenous
agentsthatalterPPARsignalingintheadult,suchasenviron-
mental agents, chemicals, or drugs, are capable of aﬀecting
lipid and glucose utilization, cholesterol biosynthesis, and
other metabolic pathways, and these attributes make PPAR
signaling an attractive target for pharmaceuticals directed at
managementofdiseasestates(diabetes,metabolicsyndrome,
hyperlipidemia) [4, 40]. This study showed that PPAR
subtypes are expressed during human fetal development
in many organs and it is likely that PPAR expression and
function during development are tightly regulated. It is not
clear whether speciﬁc agents perturb PPAR expression or
function in the fetus, whether such perturbations will have
consequences or whether eﬀects might emerge at or persist
through much later life stages. However, the demonstration
of expression of PPARα, β,a n dγ in nine major organs
during human fetal development renders consideration of
such issues highly relevant.
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